NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

NTRK遺傳基因融合陽性癌症的開發平台醫藥品:市場機會的評估,市場趨勢,流行病學的研究,開發中產品分析 (2020年下半年)

NTRK Gene Fusion Positive Cancers Pipeline Drugs - Opportunity Assessments, Market Dynamics, Epidemiological Studies, and Pipeline Analytics H2 2020

出版商 GervanoRA Data Services LLP 商品編碼 979839
出版日期 內容資訊 英文 290 Pages
訂單完成後即時交付
價格
NTRK遺傳基因融合陽性癌症的開發平台醫藥品:市場機會的評估,市場趨勢,流行病學的研究,開發中產品分析 (2020年下半年) NTRK Gene Fusion Positive Cancers Pipeline Drugs - Opportunity Assessments, Market Dynamics, Epidemiological Studies, and Pipeline Analytics H2 2020
出版日期: 2020年12月30日內容資訊: 英文 290 Pages
簡介

本報告提供全球NTRK融合遺傳基因陽性固體癌治療藥的開發平台醫藥品的市場相關分析,疾病概要和疫情趨勢預測,未滿足需求與市場機會,主要的資本交易的趨勢 (M&A,事業合作等),開發中產品的分析與臨床實驗的進展,現在、未來的競爭環境,主要企業的SWOT分析,新企業的簡介與市場機會等資訊彙整,為您概述為以下內容。

目錄

第1章 簡介

第2章 摘要整理

  • 報告概要
  • TRK抑制劑市場競爭情形:近來的主要趨勢
  • 主要的分析結果
    • 促進因素
    • 阻礙因素
    • 市場機會
  • TRK抑制劑市場競爭情形:市場動態
    • 未滿足需求與市場需求:新的治療藥的情況
    • 未滿足需求與市場需求:各給藥途徑
    • 未滿足需求與市場需求:各地區

第3章 開發平台分析:未來展望

  • 開發平台分析:現狀比較
    • 各開發階段
    • 各地區
    • 各給藥途徑
    • 各分子類型
    • 各適應症
    • 企業的各類型

第4章 TRK抑制劑療法:概要與流行病學研究

  • 簡介
  • TRK抑制劑療法:開發階段的評估
  • TRK抑制劑療法的範圍
  • NTRK融合癌症患者的檢測
  • 癌症的NTRK遺傳基因融合的發現
  • 已批准TRK抑制劑產品
  • NTRK融合遺傳基因的流行病學的研究
    • 全球過去的研究趨勢
    • NTRK融合遺傳基因的盛行率分析
    • NTRK融合遺傳基因的發病率分析
    • 被給病人藥TRK抑制劑的患者人口 (估計值)

第5章 TRK抑制劑相關的資本交易 (M&A)的分析

  • 資本交易 (企業合併、收購 (M&A),事業合作)

第6章 TRK抑制劑開發平台醫藥品的專利分析

第7章 TRK抑制劑的開發平台醫藥品分析

  • 開發平台醫藥品分析:各開發階段
    • 登記前階段的開發平台醫藥品
    • 第三階段 (III期)的開發平台醫藥品
    • 第二階段 (II期)的開發平台醫藥品
    • 第一階段 (I期)的開發平台醫藥品
    • 前臨床開發平台醫藥品
    • 初期的研發產品線醫藥品
    • 開發休止、中止的開發平台醫藥品
  • 開發平台醫藥品分析:各地區
  • 開發平台醫藥品分析:各給藥途徑
    • 口服藥
    • 外用製劑、注射藥
  • 開發平台醫藥品分析:各分子類型
  • 開發平台醫藥品分析:各標的受體
  • 開發平台醫藥品分析:各適應症
  • 開發平台醫藥品分析:企業的各類型

第8章 開發平台醫藥品的概要與開發里程碑

  • 登記前階段
  • 第三階段 (III期)
  • 第二階段 (II期)
  • 第一階段 (I期)

第9章 臨床實驗概要

  • 臨床實驗結果分析
    • 主要的臨床實驗的結果:第三階段
    • 主要的臨床實驗的結果:第二階段
    • 主要的臨床實驗的結果:第一階段
  • 進行中的臨床實驗概要
  • 最近完成的臨床實驗概要
  • 計劃中臨床實驗概要

第10章 開發平台醫藥品估計核準時間軸

  • 分析方法
  • 美國國內/國外估計核准計劃

第11章 市場機會的評估:企業間的互相比較

第12章 現在、未來的競爭情形

  • 新興企業
    • 主要的新興企業的簡介
目錄
Product Code: GERPH1903

GervanoRA's pipeline analysis and opportunity assessment report "NTRK Gene Fusion Cancers - Opportunity Assessments, Market Dynamics, Epidemiological Studies, and Pipeline Analytics H2 2020" provides detailed analytics on the Epidemiology of NTRK Gene Fusion Cancers in different regions worldwide through a keen full assessment on historical and global trends of prevalence and incidence of NTRK gene fusion-positive cancers. Based on a literature survey and further validation through the KOL process, the report emphasizes finding out the affected population with NTRK gene fusion-positive cancers by geography (US, Europe, and Worldwide) and by majorly affected cancer types. The report even provides insights on TRK Inhibitors' foreseen market opportunities considering the TRK Inhibitor therapies are the only option to treat NTRK gene fusion-positive cancers. Report further analyzed and assessed the total forecasted market into two portions considering broader scope the TRK Inhibitors to treat indications like Neurodegenerative Diseases, Gastrointestinal Diseases and addiction conditions other than NTRK gene fusion-positive cancers. The report outlines how many people can undergo TRK Inhibitor therapies by 2029, and potential market value of NTRK gene fusion-positive cancers, and the market value of TRK Inhibitors meant to treat other indications other than NTRK gene fusion-positive cancers.

TRK Inhibitors pipeline molecules have been analysed for the opportunities in the competitive space by covering all the pipeline molecules in different stages of development and all the companies which are actively involved in TRK Inhibitor drugs development pipeline.

The report has been divided into segments like TRK InhibitorsTherapies Overview and Epidemiological Studies, Market Overview, Pipeline Analytics to provide in depth insights about the market dynamics and ongoing R&D in the TRK Inhibitors area. The report provides detailed insights about all the pipeline molecules in different stages of development and all the companies which are actively involved in TRK Inhibitors drugs industry. To provide systematic pipeline analytics, we have segregated total pipeline molecules into different segments like Pipeline Analytics by Stage of Development, Pipeline Analytics by Route of Administration, Pipeline Analytics by Geography, Pipeline Analytics by Molecule Type, Pipeline Analytics by Molecule Target, Pipeline Analytics by Indication and Pipeline Analytics by Company Type.

The report has covered more than 50 companies worldwide, involved in the development of new therapeutics. Growth opportunities in the report have been provided by performing a competitive and comparative analysis on the top 10 Emerging companies in the domain and hence deriving the key leader.

Report is more focused to provide competitive opportunities by assessing and providing in-depth analytics on:

  • Unmet needs and Opportunities
  • Market Dynamics with Coverage of Deals (Licensing, Partnering, Collaborations, Financing etc.)

Epidemiological Studies of NTRK Gene Fusion Positive Cancers

  • Patent Analytics of Pipeline Molecules
  • Pipeline Analysis of all Drug Molecules and Estimated Pipeline Drug Approval Time lines of Late Clinical Stage Pipeline Drug Candidates and Filed Drug Candidates
  • Clinical Stage Drug Candidates' Descriptions along with Development Milestones
  • Plotting of the Anticipated Market Share for the New Entrants (Filed, Phase 3 and Phase 2 Drugs)
  • Opportunity Assessments through Competitive Benchmarking
  • Evaluate Current and Future Competitive Landscape through Company Profiles
  • Emerging Company Profiles with Opportunity Assessments

Report helps clients to refine the commercial opportunities from the existing treatment armamentarium to pipeline assets, deals, and deal comparables. Even it helps in identifying the most relevant actors in the field for partnering deals.

TABLE OF CONTENTS

CHAPTER 01: INTRODUCTION

  • 1.1. REPORT DESCRIPTION
  • 1.2. METHODOLOGY
  • 1.3. ABOUT US: GERVANORA DATA SERVICES

CHAPTER 02: EXECUTIVE SUMMARY

  • 2.1. REPORT SUMMARY
  • 2.2. KEY EVENTS IN THE TRK INHIBITORS COMPETITIVE SPACE
  • 2.3. REPORT MAJOR FINDINGS
    • 2.3.1. DRIVERS
    • 2.3.2. RESTRAINTS
    • 2.3.3. OPPORTUNITIES
  • 2.4. MARKET DYNAMICS OF TRK INHIBITORS COMPETITIVE LANDSCAPE
    • 2.4.1. UNMET NEEDS AND MARKET DEMANDS FOR NEWER THERAPIES
    • 2.4.2. UNMET NEEDS AND MARKET DEMANDS BY ROUTE OF ADMINISTRATION
    • 2.4.3. UNMET NEEDS AND MARKET DEMANDS BY GEOGRAPHY

CHAPTER 03: PIPELINE ANALYTICS OUTLOOK

  • 3.1. PIPELINE ANALYTICS COMPARATIVE SNAPSHOTS
    • 3.1.1. PIPELINE ANALYTICS COMPARATIVE SNAPSHOTS BY STAGE OF DEVELOPMENT
    • 3.1.2. PIPELINE ANALYTICS COMPARATIVE SNAPSHOTS BY GEOGRAPHY
    • 3.1.3. PIPELINE ANALYTICS COMPARATIVE SNAPSHOTS BY ROUTE OF ADMINISTRATION
    • 3.1.4. PIPELINE ANALYTICS COMPARATIVE SNAPSHOTS BY MOLECULE TYPE
    • 3.1.5. PIPELINE ANALYTICS COMPARATIVE SNAPSHOTS BY INDICATION
    • 3.1.6. PIPELINE ANALYTICS COMPARATIVE SNAPSHOTS BY COMPANY TYPE

CHAPTER 04: TRK INHIBITORS THERAPIES OVERVIEW AND EPIDEMIOLOGICAL STUDIES

  • 4.1. INTRODUCTION
  • 4.2. TRK INHIBITORS THERAPIES - DEVELOPMENT ASSESSMENTS
  • 4.3. SCOPE OF TRK INHIBITORS THERAPIES
  • 4.4. DETECTION OF PATIENTS WITH NTRK FUSION CANCERS
  • 4.5. DISCOVERY OF NTRK GENE FUSIONS IN CANCERS
  • 4.6. APPROVED TRK INHIBITOR PRODUCTS
  • 4.7. EPIDEMIOLOGICAL STUDIES OF NTRK GENE FUSIONS
    • 4.7.1. GLOBAL AND HISTORICAL TRENDS
    • 4.7.2. PREVALENCE STUDIES OF NTRK GENE FUSIONS
      • 4.7.2.1. PREVALENCE OF NTRK GENE FUSIONS IN CANCER TYPES
      • 4.7.2.2. PREVALENCE OF NTRK GENE FUSIONS BY GEOGRAPHY
      • 4.7.2.3. PREVALENCE OF NTRK GENE FUSIONS BY AGE GROUP
    • 4.7.3. INCIDENCE STUDIES OF NTRK GENE FUSIONS
      • 4.7.3.1. INCIDENCE OF NTRK GENE FUSIONS IN CANCER TYPES
      • 4.7.3.2. INCIDENCE OF NTRK GENE FUSIONS BY GEOGRAPHY
    • 4.7.4. ESTIMATED PATIENT POPULATION WHO RECEIVE TRK INHIBITORS

CHAPTER 05: DEALS (M&A) ANALYTICS OF TRK INHIBITORS

  • 5.1. DEALS (MERGERS/ACQUISITIONS/COLLABORATIONS)

CHAPTER 06: PATENT ANALYTICS OF TRK INHIBITORS PIPELINE DRUGS

CHAPTER 07: PIPELINE DRUGS ANALYTICS OF TRK INHIBITORS

  • 7.1. PIPELINE DRUGS ANALYTICS BY STAGE OF DEVELOPMENT
    • 7.1.1. PRE-REGISTRATION STAGE PIPELINE DRUGS
    • 7.1.2. PHASE III PIPELINE DRUGS
    • 7.1.3. PHASE II PIPELINE DRUGS
    • 7.1.4. PHASE I PIPELINE DRUGS
    • 7.1.5. PRE-CLINICAL PIPELINE DRUGS
    • 7.1.6. EARLY R&D PIPELINE DRUGS
    • 7.1.7. INACTIVE AND DISCONTINUED PIPELINE DRUGS
  • 7.2. PIPELINE DRUGS ANALYTICS BY GEOGRAPHY
  • 7.3. PIPELINE DRUGS ANALYTICS BY ROUTE OF ADMINISTRATION
    • 7.3.1. PIPELINE ANALYTICS BY ORAL ROUTE OF ADMINISTRATION
    • 7.3.2. PIPELINE ANALYTICS BY TOPICAL AND INJECTABLE ROA
  • 7.4. PIPELINE DRUGS ANALYTICS BY MOLECULE TYPE
  • 7.5. PIPELINE DRUGS ANALYTICS BY TARGET RECEPTORS
  • 7.6. PIPELINE DRUGS ANALYTICS BY INDICATIONS
  • 7.7. PIPELINE DRUGS ANALYTICS BY COMPANY TYPE

CHAPTER 08: PIPELINE DRUGS DESCRIPTIONS AND DEVELOPMENT MILESTONES

  • 8.1. PRE-REGISTRATION PIPELINE DRUGS DESCRIPTIONS AND DEVELOPMENT MILESTONES
  • 8.2. PHASE III PIPELINE DRUGS DESCRIPTIONS AND DEVELOPMENT MILESTONES
  • 8.3. PHASE II PIPELINE DRUGS DESCRIPTIONS AND DEVELOPMENT MILESTONES
  • 8.4. PHASE I PIPELINE DRUGS DESCRIPTIONS AND DEVELOPMENT MILESTONES

CHAPTER 09: CLINICAL TRIALS SUMMARY

  • 9.1. ANALYSIS BY CLINICAL TRIAL RESULTS
    • 9.1.1. KEY PHASE III CLINICAL TRIAL RESULTS
    • 9.1.2. KEY PHASE II CLINICAL TRIAL RESULTS
    • 9.1.3. KEY PHASE I CLINICAL TRIAL RESULTS
  • 9.2. ONGOING CLINICAL TRIALS SUMMARY
  • 9.3. RECENTLY COMPLETED CLINICAL TRIALS SUMMARY
  • 9.4. PLANNED CLINICAL TRIALS SUMMARY

CHAPTER 10: ESTIMATED APPROVAL TIMELINES OF PIPELINE DRUGS

  • 10.1. METHODOLOGY
  • 10.2. ESTIMATED APPROVAL TIMELINES US & EX-US

CHAPTER 11: OPPORTUNITY ASSESSMENTS THROUGH COMPETITIVE BENCH-MARKING

CHAPTER 12: CURRENT AND FUTURE COMPETITIVE LANDSCAPE

  • 12.1. EMERGING COMPANIES
    • 12.1.1. EMERGING COMPANY PROFILES